Literature DB >> 19220073

Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension.

Monique P Curran1, Jennifer S Orman.   

Abstract

Topically administered bimatoprost 0.03%/timolol 0.5% ophthalmic solution (bimatoprost/timolol: Ganfort) comprises the synthetic prostamide bimatoprost (structurally related to prostaglandin F2 alpha) and the beta-adrenergic receptor antagonist timolol. Bimatoprost/timolol (one drop administered in the affected eye[s] once daily in the morning or evening) is an effective and well tolerated fixed combination for lowering intra-ocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (OHT), including individuals uncontrolled on monotherapy with a beta-adrenergic receptor antagonist or prostaglandin analogue/prostamide.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19220073     DOI： 10.2165/0002512-200926020-00008

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


  52 in total

1.  Pharmacological considerations in the treatment of glaucoma.

Authors:  Richard G Fiscella
Journal:  Manag Care       Date:  2002-01

Review 2.  Medical management of glaucoma.

Authors:  Casey C Geringer; Nauman R Imami
Journal:  Int Ophthalmol Clin       Date:  2008

3.  Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.

Authors:  Joel S Schuman; Gregory J Katz; Richard A Lewis; J Charles Henry; Sushanta Mallick; David T Wells; E Kenneth Sullivan; Theresa A Landry; Michael V W Bergamini; Stella M Robertson
Journal:  Am J Ophthalmol       Date:  2005-08       Impact factor: 5.258

4.  A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.

Authors:  Bret A Hughes; Jason Bacharach; E Randy Craven; Martin B Kaback; Sushanta Mallick; Theresa A Landry; Michael V W Bergamini
Journal:  J Glaucoma       Date:  2005-10       Impact factor: 2.503

Review 5.  Management of glaucoma: focus on pharmacological therapy.

Authors:  Robert E Marquis; Jess T Whitson
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  [Comparison of intraocular pressure lowering efficacy of bimatoprost / timolol fixed combination and other glaucoma medications in the treatment of glaucoma].

Authors:  K Skorkovská
Journal:  Cesk Slov Oftalmol       Date:  2008-07

7.  The number of people with glaucoma worldwide in 2010 and 2020.

Authors:  H A Quigley; A T Broman
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

8.  Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

9.  The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

10.  Compliance in patients prescribed eyedrops for glaucoma.

Authors:  S C Patel; G L Spaeth
Journal:  Ophthalmic Surg       Date:  1995 May-Jun
View more
  7 in total

1.  Upregulation of Homer1a Promoted Retinal Ganglion Cell Survival After Retinal Ischemia and Reperfusion via Interacting with Erk Pathway.

Authors:  Fei Fei; Juan Li; Wei Rao; Wenbo Liu; Xiaoyan Chen; Ning Su; Yusheng Wang; Zhou Fei
Journal:  Cell Mol Neurobiol       Date:  2015-04-30       Impact factor: 5.046

2.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

3.  Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents.

Authors:  Uttio Roy Chowdhury; Tommy A Rinkoski; Cindy K Bahler; J Cameron Millar; Jacques A Bertrand; Bradley H Holman; Joseph M Sherwood; Darryl R Overby; Kristen L Stoltz; Peter I Dosa; Michael P Fautsch
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-11-01       Impact factor: 4.799

Review 4.  Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

5.  Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients.

Authors:  M Francesca Cordeiro; Ivan Goldberg; Rhett Schiffman; Paula Bernstein; Marina Bejanian
Journal:  Clin Ophthalmol       Date:  2015-08-31

6.  Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.

Authors:  Alfonso García-López; José A Paczka; Jesús Jiménez-Román; Curt Hartleben
Journal:  BMC Ophthalmol       Date:  2014-12-19       Impact factor: 2.209

7.  Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial.

Authors:  Ivan Goldberg; Rafael Gil Pina; Aitor Lanzagorta-Aresti; Rhett M Schiffman; Charlie Liu; Marina Bejanian
Journal:  Br J Ophthalmol       Date:  2014-03-25       Impact factor: 4.638
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.